Author:
Høilund-Carlsen Poul F.,Alavi Abass,Barrio Jorge R.,Castellani Rudolph J.,Costa Tommaso,Herrup Karl,Kepp Kasper P.,Neve Rachael L.,Perry George,Revheim Mona-Elisabeth,Robakis Nikolaos K.,Sensi Stefano L.,Vissel Bryce
Reference33 articles.
1. Accelerated brain volume loss caused by anti-β-amyloid drugs: a systematic review and meta-analysis;Alves;Neurology,2023
2. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials;Andrews;Alzheimers Dement,2019
3. Biogen. 2024. Biogen to Realign Resources for Alzheimer's Disease Franchise [Online]. 31 January 2024. 〈https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise〉. [Accessed 04.01.2024].
4. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease;Budd Haeberlein;J. Prev. Alzheimers Dis.,2022
5. Neuropathology of anti-amyloid-β immunotherapy: a case report. 2023;Castellani;J. Alzheimers Dis.,2023
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献